SAN-SITA-MP
Description_Effects
SAN-SITA-MP is a combination antidiabetic medication that contains Sitagliptin 100 mg, Metformin Hydrochloride (Sustained Release) 500 mg, and Pioglitazone 15 mg. This triple-drug formulation is used to effectively manage blood sugar levels in adults with type 2 diabetes mellitus, especially in cases where single or dual therapy does not provide adequate control. Sitagliptin is a DPP-4 inhibitor that works by increasing levels of incretin hormones, which in turn helps the body release more insulin and reduces the amount of glucose produced by the liver, particularly after meals. Metformin is a biguanide that lowers glucose production in the liver, improves the body’s response to insulin, and decreases glucose absorption from the intestine. Pioglitazone, a thiazolidinedione, works by improving insulin sensitivity in muscle and fat tissues and also helps reduce hepatic glucose output. Together, these three medications target different mechanisms in the body to provide comprehensive glycemic control. This combination can help lower HbA1c levels, improve insulin sensitivity, and reduce fasting and postprandial glucose levels. SAN-SITA-MP is typically used alongside a proper diet and regular physical activity. It should be taken as prescribed by a healthcare professional, and regular monitoring of blood sugar levels is recommended for best results.
